
    
      This study has two sequential parts:

        -  Part 1: 6-month double-blind period in which subjects will be randomized to receive
           either inclisiran or placebo on Days 1 and 90

        -  Part 2: 18-month open-label follow-up period; placebo-treated subjects from Part 1 will
           be transitioned to inclisiran on Day 180 and all subjects will participate in an
           open-label follow-up period of inclisiran only
    
  